RPG Life Sciences Limited

Net sales rose by 12.7% year-over-year (YoY) to Rs 143.09 crore during the period under review. Total operating expenditure aggregated to Rs 117.60 crore in the quarter ended 31 March 2025, up by 10.7% YoY. Recorded EBITDA margin expanded from 23.3% in Q4 FY25 to 26.4% in Q4 FY25. In the March 2025 quarter, the company has recorded a profit of Rs 126.23 crore, which has resulted from assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai. During the quarter, a fire incident had occurred at the company's manufacturing unit located at Navi Mumbai. The company had recognized an initial loss of Rs 24.83 crore and a corresponding credit of the two tranches of interim payment from the insurance company of Rs 8.50 crore, resulting in net initial loss of Rs 16.33 crore. These two items have resulted in the company recording a net exceptional gain of Rs 109.90 crore in Q4 FY25. Accordingly, profit before tax in Q4 FY25 stood at Rs 134.90 crore, up by 660.4% from Rs 17.74 crore recorded in Q4 FY24. Tax outgo for the fourth quarter was Rs 17.48 crore, up 220.7% YoY. RPG Life has reported 34.9% rise in net profit to Rs 118.26 crore on a 12.3% increase in net sales to Rs 653.43 crore in FY25 as compared with FY24. Yugal Sikri, managing director, RPG Life Sciences, said: Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market. Thanks to our five pillar strategy, we are building brands, portfolios and therapies; increasing sales force productivity and nurturing strategic business assets. We are quite on course in shaping our International Formulations and API businesses to emerge as second and third growth engines by way of modernisation of both our API and Formulations plants, setting up new R&D units, developing a strong product pipeline, by infusion of significant capex. The International Formulations business is registering healthy double-digit profitable growth, and the API business is also showing promising profitable growth. Our structural approach of cost optimisation has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory. The company has built sizeable cash surplus of Rs 168 crore from operations as a result of continued remarkable business performance. Additional cash generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant has further augmented the pool to Rs. 266 crore. We are actively pursuing inorganic opportunities to accelerate business growth.' RPG Life Sciences, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Powered by Capital Market - Live

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held on 28 April 2025, inter alia, have recommended the final dividend of Rs 20 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held on 28 April 2025, inter alia, have recommended the special dividend of Rs 4 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of RPG Life Sciences rose 786.33% to Rs 117.35 crore in the quarter ended March 2025 as against Rs 13.24 crore during the previous quarter ended March 2024. Sales rose 12.68% to Rs 143.09 crore in the quarter ended March 2025 as against Rs 126.99 crore during the previous quarter ended March 2024. For the full year,net profit rose 109.03% to Rs 183.24 crore in the year ended March 2025 as against Rs 87.66 crore during the previous year ended March 2024. Sales rose 12.26% to Rs 653.43 crore in the year ended March 2025 as against Rs 582.05 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales143.09126.99 13 653.43582.05 12 OPM %17.8116.32 -24.4322.02 - PBDT30.3722.23 37 171.71134.91 27 PBT25.0017.74 41 150.28117.84 28 NP117.3513.24 786 183.2487.66 109 Powered by Capital Market - Live

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 28 April 2025.Powered by Capital Market - Live

Profit before tax (PBT) gained 31.93% to Rs 46.89 crore in Q3 FY25 from Rs 35.54 crore in Q3 FY24. Total expenses added 7.53% YoY to Rs 129.13 crore during the quarter. Employee benefits expense stood at Rs 28.71 crore (down 14.78% YoY), and finance costs came in at Rs 0.12 (down 14.28% YoY). On a nine-month basis, the company's consolidated net profit tumbled 11.46% to Rs 65.89 crore despite a 12.14% increase in revenue from operations to Rs 510.34 crore in 9M FY25 over 9M FY24. RPG Life Sciences in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). Powered by Capital Market - Live

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live

Net profit of RPG Life Sciences declined 83.76% to Rs 4.20 crore in the quarter ended September 2024 as against Rs 25.86 crore during the previous quarter ended September 2023. Sales rose 12.13% to Rs 172.21 crore in the quarter ended September 2024 as against Rs 153.58 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales172.21153.58 12 OPM %26.6724.28 - PBDT47.7039.02 22 PBT42.3934.79 22 NP4.2025.86 -84 Powered by Capital Market - Live